News from Bayer
July 04, 2022
Not intended for U.S. and UK Media – New late-breaking data from Phase III ARASENS trial presented in the Game Changer oral session at the European Association of Urology Congress 2022 (EAU22)
Darolutamide plus androgen deprivation therapy and docetaxel demonstrates consistent overall survival benefits across various patient segments in metastatic hormone-sensitive prostate cancer
June 30, 2022
Not intended for U.S. and UK Media
Kerendia™ (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
June 29, 2022
Not intended for U.S. and UK Media
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
Explore All Stories
Please enter a term to search